Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Published in: Digestive Diseases and Sciences 5/2011

01-05-2011 | Original Article

Small Intestinal Bacterial Overgrowth in Nonalcoholic Steatohepatitis: Association with Toll-Like Receptor 4 Expression and Plasma Levels of Interleukin 8

Authors: Ahmed Abu Shanab, Paul Scully, Orla Crosbie, Martin Buckley, Liam O’Mahony, Fergus Shanahan, Sanaa Gazareen, Eileen Murphy, Eamonn M. M. Quigley

Published in: Digestive Diseases and Sciences | Issue 5/2011

Login to get access

Abstract

Background

Experimental and clinical studies suggest an association between small intestinal bacterial overgrowth (SIBO) and nonalcoholic steatohepatitis (NASH). Liver injury and fibrosis could be related to exposure to bacterial products of intestinal origin and, most notably, endotoxin, including lipopolysaccharide (LPS).

Aim

To compare the prevalence of SIBO and its relationships to LPS receptor levels and systemic cytokines in NASH patients and healthy control subjects.

Methods

Eighteen NASH patients (eight males) and 16 age-matched and gender-matched healthy volunteers were studied. SIBO was assessed by the lactulose breath hydrogen test (LHBT), plasma lipopolysaccharide binding protein (LBP) levels by ELISA, and expression (as a percentage) of TLR-2 and 4 on CD14-positive cells by flow cytometry. Pro-inflammatory cytokines (IL-1β, IL-6, IL-8, and TNF-α) were measured in plasma.

Results

SIBO was more common in NASH patients than control subjects (77.78% vs. 31.25%; P < 0.0001). LBP levels and TLR-2 expression were similar in both groups, TLR-4/MD-2 expression on CD14 positive cells was higher among NASH patients: expression, mean ± SEM, NASH vs. control: 20.95 ± 2.91% vs. 12.73 ± 2.29%, P < 0.05. Among the examined cytokines, only IL-8 levels were significantly higher in patients than control (P = 0.04) and correlated positively with TLR-4 expression (r = 0.5123, P = 0.036).

Conclusion

NASH patients have a higher prevalence of small intestinal bacterial overgrowth which is associated with enhanced expression of TLR-4 and release of IL-8. SIBO may have an important role in NASH through interactions with TLR-4 and induction of the pro-inflammatory cytokine, IL-8.
Literature
1.
Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity. Gastroenterology. 1999;116:1413–1419.PubMed
2.
Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–1321.PubMed
3.
Maeda T, Hashimoto K, Kihara Y, et al. Surgically resected hepatocellular carcinomas in patients with non-alcoholic steatohepatitis. Hepatogastroenterology. 2008;55:1404–1406.PubMed
4.
Day CP, James O. Steatohepatitis: A tale of two “hits”? Gastroenterology. 1998;114:842–845.PubMed
5.
Day CP. Non-alcoholic steatohepatitis (NASH): Where are we now and where are we going? Gut. 2002;50:585–588.PubMed
6.
Namikawa C, Zhang H, Toi M. Non-alcoholic steatohepatitis: Pathology and pathogenesis. Nippon Rinsho. 2006;64:1107–1113.PubMed
7.
Nazim M, Stamp G, Hodgson HJ. Non-alcoholic steatohepatitis associated with small intestinal diverticulosis and bacterial overgrowth. Hepatogastroenterology. 1989;36:349–351.PubMed
8.
Zhao LF, Jia JM, Han DW. The role of enterogenous endotoxemia in the pathogenesis of non-alcoholic steatohepatitis. Zhonghua Gan Zang Bing Za Zhi. 2004;12:632.PubMed
9.
Fu JF, Fang YL, Liang L, et al. A rabbit model of pediatric nonalcoholic steatohepatitis: The role of adiponectin. World J Gastroenterol. 2009;15:912–918.PubMed
10.
Soza A, Riquelme A, Gonzalez R, et al. Increased orocecal transit time in patients with nonalcoholic fatty liver disease. Dig Dis Sci. 2005;50:1136–1140.PubMed
11.
Fan JG, Xu ZJ, Wang GL. Effect of lactulose on establishment of a rat non-alcoholic steatohepatitis model. World J Gastroenterol. 2005;11:5053–5056.PubMed
12.
Wigg AJ, Roberts-Thomson IC, Dymock RB, et al. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut. 2001;48:206–211.PubMed
13.
Riordan SM, McIver CJ, Williams R. Liver damage in human small intestinal bacterial overgrowth. Am J Gastroenterol. 1998;93:234–237.PubMed
14.
Wu WC, Zhao W, Li S. Small intestinal bacteria overgrowth decreases small intestinal motility in the NASH rats. World J Gastroenterol. 2008;14:313–317.PubMed
15.
Cuoco L, Montalto M, Jorizzo RA, et al. Eradication of small intestinal bacterial overgrowth and oro-cecal transit in diabetics. Hepatogastroenterology. 2002;49:1582–1586.PubMed
16.
Basilisco G, Camboni G, Bozzani A, et al. Orocecal transit delay in obese patients. Dig Dis Sci. 1989;34:509–512.PubMed
17.
Sabate JM, Jouet P, Harnois F, et al. High prevalence of small intestinal bacterial overgrowth in patients with morbid obesity: A contributor to severe hepatic steatosis. Obes Surg. 2008;18:371–377.PubMed
18.
Pilotto A, Franceschi M, Del Favero G, et al. The effect of aging on oro-cecal transit time in normal subjects and patients with gallstone disease. Aging (Milano). 1995;7:234–237.
19.
Elphick DA, Chew TS, Higham SE, et al. Small bowel bacterial overgrowth in symptomatic older people: Can it be diagnosed earlier? Gerontology. 2005;51:396–401.PubMed
20.
Madrid AM, Cumsille F, Defilippi C. Altered small bowel motility in patients with liver cirrhosis depends on severity of liver disease. Dig Dis Sci. 1997;42:738–742.PubMed
21.
Chesta J, Defilippi C, Defilippi C. Abnormalities in proximal small bowel motility in patients with cirrhosis. Hepatology. 1993;17:828–832.PubMed
22.
Gunnarsdottir SA, Sadik R, Shev S, et al. Small intestinal motility disturbances and bacterial overgrowth in patients with liver cirrhosis and portal hypertension. Am J Gastroenterol. 2003;98:1362–1370.PubMed
23.
Chang CS, Chen GH, Lien HC, et al. Small intestine dysmotility and bacterial overgrowth in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology. 1998;28:1187–1190.PubMed
24.
Pardo A, Bartoli R, Lorenzo-Zuniga V, et al. Effect of cisapride on intestinal bacterial overgrowth and bacterial translocation in cirrhosis. Hepatology. 2000;31:858–863.PubMed
25.
Gao Y, Song LX, Jiang MN, et al. Effects of traditional Chinese medicine on endotoxin and its receptors in rats with non-alcoholic steatohepatitis. Inflammation. 2008;31:121–132.PubMed
26.
Dumas ME, Barton RH, Toye A, et al. Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. Proc Natl Acad Sci U S A. 2006;103:12511–12516.PubMed
27.
Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56:1761–1772.PubMed
28.
Yang SQ, Lin HZ, Lane MD, et al. Obesity increases sensitivity to endotoxin liver injury: Implications for the pathogenesis of steatohepatitis. Proc Natl Acad Sci U S A. 1997;94:2557–2562.PubMed
29.
Drewe J, Beglinger C, Fricker G. Effect of ischemia on intestinal permeability of lipopolysaccharides. Eur J Clin Invest. 2001;31:138–144.PubMed
30.
Neal MD, Leaphart C, Levy R, et al. Enterocyte TLR4 mediates phagocytosis and translocation of bacteria across the intestinal barrier. J Immunol. 2006;176:3070–3079.PubMed
31.
Moore FA, Moore EE, Poggetti R, et al. Gut bacterial translocation via the portal vein: A clinical perspective with major torso trauma. J Trauma. 1991;31:629–636.PubMed
32.
Tomita M, Ohkubo R, Hayashi M. Lipopolysaccharide transport system across colonic epithelial cells in normal and infective rat. Drug Metab Pharmacokinet. 2004;19:33–40.PubMed
33.
Wright SD, Ramos RA, Tobias PS, et al. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science. 1990;249:1431–1433.PubMed
34.
Vreugdenhil AC, Rousseau CH, Hartung T, et al. Lipopolysaccharide (LPS)-binding protein mediates LPS detoxification by chylomicrons. J Immunol. 2003;170:1399–1405.PubMed
35.
Wu RQ, Xu YX, Song XH, et al. Adhesion molecule and proinflammatory cytokine gene expression in hepatic sinusoidal endothelial cells following cecal ligation and puncture. World J Gastroenterol. 2001;7:128–130.PubMed
36.
Gutsmann T, Muller M, Carroll SF, et al. Dual role of lipopolysaccharide (LPS)-binding protein in neutralization of LPS and enhancement of LPS-induced activation of mononuclear cells. Infect Immun. 2001;69:6942–6950.PubMed
37.
Heumann D, Adachi Y, Le Roy D, et al. Role of plasma, lipopolysaccharide-binding protein, and CD14 in response of mouse peritoneal exudate macrophages to endotoxin. Infect Immun. 2001;69:378–385.PubMed
38.
Tobias PS, Soldau K, Gegner JA, et al. Lipopolysaccharide binding protein-mediated complexation of lipopolysaccharide with soluble CD14. J Biol Chem. 1995;270:10482–10488.PubMed
39.
Romics L Jr, Mandrekar P, Kodys K, Velayudham A, Drechsler Y, Dolganiuc A, Szabo G. Increased lipopolysaccharide sensitivity in alcoholic fatty livers is independent of leptin deficiency and toll-like receptor 4 (TLR4) or TLR2 mRNA expression. Alcohol Clin Exp Res. 2005;9:1018–1026.
40.
Medvedev AE, Vogel SN. Overexpression of CD14, TLR4, and MD-2 in HEK 293T cells does not prevent induction of in vitro endotoxin tolerance. J Endotoxin Res. 2003;9:60–64.PubMed
41.
Nagai Y, Akashi S, Nagafuku M, et al. Essential role of MD-2 in LPS responsiveness and TLR4 distribution. Nat Immunol. 2002;3:667–672.PubMed
42.
Tazi KA, Quioc JJ, Saada V, et al. Upregulation of TNF-alpha production signaling pathways in monocytes from patients with advanced cirrhosis: Possible role of Akt and IRAK-M. J Hepatol. 2006;45:280–289.PubMed
43.
Paik YH, Schwabe RF, Bataller R, et al. Toll-like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells. Hepatology. 2003;37:1043–1055.PubMed
44.
Thurman RG, Bradford BU, Knecht KT, et al. Endotoxin, Kupffer cells and alcoholic liver injury. In: Blum HE, Bode Ch, Bode JCh, Sartor RB (ed) Gut and the liver. Falk Symposium 100, Dordrecht, The Netherlands. Kluwer Academic Publishers Group, 1997:222–240.
45.
Bode Ch, Schafer C, Bode JCh. The role of gut derived bacterial toxins (endotoxin) for the development of alcoholic liver disease in man. In: Blum HE, Bode Ch, Bode JCh, Sartor RB (ed) Gut and the liver. Falk Symposium 100, Dordrecht, The Netherlands. Kluwer Academic Publishers Group, 1997:281–298.
46.
McClain CJ, Song Z, Barve SS, et al. Recent advances in alcoholic liver disease. IV. Dysregulated cytokine metabolism in alcoholic liver disease. Am J Physiol Gastrointest Liver Physiol. 2004;287:G497–G502.PubMed
47.
Copaci I, Micu L, Voiculescu M. The role of cytokines in non-alcoholic steatohepatitis. A review. J Gastrointest Liver Dis. 2006;15:363–373.
48.
Hui JM, Hodge A, Farrell GC, et al. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology. 2004;40:46–54.PubMed
49.
Kugelmas M, Hill DB, Vivian B, et al. Cytokines and NASH: A pilot study of the effects of lifestyle modification and vitamin E. Hepatology. 2003;38:413–419.PubMed
50.
Crespo J, Cayon A, Fernandez-Gil P, et al. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology. 2001;34:1158–1163.PubMed
51.
Feldstein AE, Werneburg NW, Canbay A, et al. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology. 2004;40:185–194.PubMed
52.
Jung BD, Kimura K, Kitamura H, et al. Norepinephrine stimulates interleukin-6 mRNA expression in primary cultured rat hepatocytes. J Biochem. 2000;127:205–209.PubMed
53.
Tilg H, Diehl AM. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med. 2000;343:1467–1476.PubMed
54.
West DA, James NH, Cosulich SC, et al. Role for tumor necrosis factor a receptor 1 and interleukin-1 receptor in the suppression of mouse hepatocyte apoptosis by the peroxisome proliferator nafenopin. Hepatology. 1999;30:1417–1424.PubMed
55.
Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest. 2004;114:147–152.PubMed
56.
Nonalcoholic steatohepatitis clinical research network. Hepatology. 2003;37:244.
57.
Kerlin P, Wong L. Breath hydrogen testing in bacterial overgrowth of the small intestine. Gastroenterology. 1988;95:982–988.PubMed
58.
Corazza GR, Strocchi A, Gasbarrini G. Fasting breath hydrogen in celiac disease. Gastroenterology. 1987;93:53–58.PubMed
59.
Perman JA, Modler S, Barr RG, et al. Fasting breath hydrogen concentration: Normal values and clinical application. Gastroenterology. 1984;87:1358–1363.PubMed
60.
Sharara AI, Aoun E, Abdul-Baki H, et al. A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol. 2006;101:326–333.PubMed
61.
Posserud I, Stotzer PO, Bjornsson ES, et al. Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut. 2007;56:802–808.PubMed
62.
Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. A double-blind, randomized, placebo-controlled study. Am J Gastroenterol. 2003;98:412–419.PubMed
63.
Walters B, Vanner SJ. Detection of bacterial overgrowth in IBS using the lactulose H2 breath test: Comparison with 14C-D-xylose and healthy controls. Am J Gastroenterol. 2005;100:1566–1570.PubMed
64.
Bratten JR, Spanier J, Jones MP. Lactulose hydrogen breath testing (LHBT) in patients with IBS and controls: Differences in methane (CH4) but not hydrogen (H2). Am J Gastroenterol. 2006;101:S479.
65.
Simon D, Borelli S, Braathen LR, Simon HU. Peripheral blood mononuclear cells from IgE- and non-IgE-associated allergic atopic eczema/dermatitis syndrome (AEDS) demonstrate increased capacity of generating interleukin-13 but differ in their potential of synthesizing interferon-gamma. Allergy. 2002;57:431–435.PubMed
66.
Bihl T, Vassina E, Boettger MK, et al. The T348M mutated form of cryopyrin is associated with defective lipopolysaccharide-induced interleukin 10 production in CINCA syndrome. Ann Rheum Dis. 2005;64:1380–1381.PubMed
67.
de Oliveira CP, Stefano JT, de Siqueira ER, et al. Combination of N-acetylcysteine and metformin improves histological steatosis and fibrosis in patients with non-alcoholic steatohepatitis. Hepatol Res. 2008;38:159–165.PubMed
68.
Gisbert JP, Gonzalez-Lama Y. Breath tests in the diagnosis of gastrointestinal diseases. Gastroenterol Hepatol. 2005;28:407–416.PubMed
69.
Kristensen M, Hoeck HC. Abnormal flora in the small intestine. Diagnostic evaluation of the H2 breath test. Ugeskr Laeger. 1994;156:7530–7533.PubMed
70.
Romagnuolo J, Schiller D, Bailey RJ. Using breath tests wisely in a gastroenterology practice: An evidence-based review of indications and pitfalls in interpretation. Am J Gastroenterol. 2002;97:1113–1126.PubMed
71.
Bauer TM, Schwacha H, Steinbruckner B, et al. Diagnosis of small intestinal bacterial overgrowth in patients with cirrhosis of the liver: Poor performance of the glucose breath hydrogen test. J Hepatol. 2000;33:382–386.PubMed
72.
Farrell G. Is bacterial ash the flash that ignites NASH? Gut. 2001;48:148–149.PubMed
73.
Sajjad A, Mottershead M, Syn WK, et al. Ciprofloxacin suppresses bacterial overgrowth, increases fasting insulin but does not correct low acylated ghrelin concentration in non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2005;22:291–299.PubMed
74.
Reilly JA Jr, Quigley EM, Forst CF, et al. Small intestinal transit in the portal hypertensive rat. Gastroenterology. 1991;100:670–674.PubMed
75.
Casafont Morencos F, de las Heras Castano G, Martin Ramos L, et al. Small bowel bacterial overgrowth in patients with alcoholic cirrhosis. Dig Dis Sci. 1996;41:552–556.PubMed
76.
Prytz H, Holst-Christensen J, Korner B, et al. Portal venous and systemic endotoxaemia in patients without liver disease and systemic endotoxaemia in patients with cirrhosis. Scand J Gastroenterol. 1976;11:857–863.PubMed
77.
Lumsden AB, Henderson JM, Kutner MH. Endotoxin levels measured by a chromogenic assay in portal, hepatic and peripheral venous blood in patients with cirrhosis. Hepatology. 1988;8:232–236.PubMed
78.
Hurley JC, Tosolini FA, Louis WJ. Quantitative limulus lysate assay for endotoxin and the effect of plasma. J Clin Pathol. 1991;44:849–854.PubMed
79.
Jin X, Yu CH, Lv GC, et al. Increased intestinal permeability in pathogenesis and progress of nonalcoholic steatohepatitis in rats. World J Gastroenterol. 2007;13:1732–1736.PubMed
80.
Tarao K, So K, Moroi T, et al. Detection of endotoxin in plasma and ascitic fluid of patients with cirrhosis: Its clinical significance. Gastroenterology. 1977;73:539–542.PubMed
81.
Ruiz AG, Casafont F, Crespo J, et al. Lipopolysaccharide-binding protein plasma levels and liver TNF-alpha gene expression in obese patients: Evidence for the potential role of endotoxin in the pathogenesis of non-alcoholic steatohepatitis. Obes Surg. 2007;17:1374–1380.PubMed
82.
Kopp E, Medzhitov R. Recognition of microbial infection by toll-like receptors. Curr Opin Immunol. 2003;15:396–401.PubMed
83.
Igolnikov AC, Green RM. C3H/HEJ mice with mutations of the toll-like receptor 4 (TLR-4) are resistant to the methionine-choline deficient (MCD) diet induced non-alcoholic steatohepatitis (NASH). Hepatology. 2003;36:A404.
84.
Rivera CA, Adegboyega P, van Rooijen N, et al. Toll-like receptor-4 signaling and kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J Hepatol. 2007;47:571–579.PubMed
85.
Stadlbauer V, Mookerjee RP, Hodges S, et al. Effect of probiotic treatment on deranged neutrophil function and cytokine responses in patients with compensated alcoholic cirrhosis. J Hepatol. 2008;48:945–951.PubMed
86.
Szabo G, Velayudham A, Romics L Jr, et al. Modulation of non-alcoholic steatohepatitis by pattern recognition receptors in mice: The role of toll-like receptors 2 and 4. Alcohol Clin Exp Res. 2005;29(11 Suppl):140S–145S.PubMed
87.
Tuncer I, Özbek H, Topal H, Uygan I. The serum levels of IL-1B, Il-6, IL-8 and TNF alpha in non alcoholic fatty liver disease. Turk J Med Sci. 2003;33:381–386.
88.
Bahcecioglu IH, Yalniz M, Ataseven H, et al. Levels of serum hyaluronic acid, TNF-alpha and IL-8 in patients with nonalcoholic steatohepatitis. Hepatogastroenterology. 2005;52:1549–1553.PubMed
89.
Torer N, Ozenirler S, Yucel A, et al. Importance of cytokines, oxidative stress and expression of BCL-2 in the pathogenesis of non-alcoholic steatohepatitis. Scand J Gastroenterol. 2007;42:1095–1101.PubMed
90.
Jarrar MH, Baranova A, Collantes R, et al. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2008;27:412–421.PubMed
91.
Yin M, Wheeler MD, Kono H, et al. Essential role of tumor necrosis factor alpha in alcohol-induced liver injury in mice. Gastroenterology. 1999;117:942–952.PubMed
92.
McClain C, Hill D, Schmidt J, et al. Cytokines and alcoholic liver disease. Semin Liver Dis. 1993;13:170–182.PubMed
93.
Wolff B, Burns AR, Middleton J, et al. Endothelial cell “memory” of inflammatory stimulation: Human venular endothelial cells store interleukin 8 in Weibel-Palade bodies. J Exp Med. 1998;188:1757–1762.PubMed
94.
Mohler KM, Sleath PR, Fitzner JN, et al. Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing. Nature. 1994;370:218–220.PubMed
95.
Ashkenazi A, Marsters SA, Capon DJ, et al. Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin. Proc Natl Acad Sci USA. 1991;88:10535–10539.PubMed
96.
Zhang H, Feng Q, Li HS, et al. Effects of Qushi Huayu Decoction on cathepsin B and tumor necrosis factor-alpha expression in rats with non-alcoholic steatohepatitis. Zhong Xi Yi Jie He Xue Bao. 2008;6:928–933.PubMed
97.
Diehl AM. Tumor necrosis factor and its potential role in insulin resistance and nonalcoholic fatty liver disease. Clin Liver Dis. 2004;8:619–638.PubMed
98.
Lesmana CR, Lesmana LA, Akbar N, et al. Clinical picture, insulin resistance, and adipocytokines profiles of nonalcoholic steatohepatitis (NASH) patients in Indonesia. Acta Med Indones. 2009;41:6–10.PubMed
99.
Schramm C, Schneider A, Marx A, Lohse AW. Adalimumab could suppress the activity of non alcoholic steatohepatitis (NASH). Z Gastroenterol. 2008;46:1369–1371.PubMed
100.
Tomita K, Tamiya G, Ando S, et al. Tumour necrosis factor alpha signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice. Gut. 2006;55:415–424.PubMed
101.
Roilides E, Katsifa H, Tsaparidou S, et al. Interleukin 10 suppresses phagocytic and antihyphal activities of human neutrolphils. Cytokine. 2000;12:379–387.PubMed
102.
Laichalk LL, Danforth JM, Standiford TJ. Interleukin-10 inhibits neutrophil phagocytic and bactericidal activity. FEMS Immunol Med Microbiol. 1996;15:181–187.PubMed
103.
Poniachik J, Csendes A, Diaz JC, et al. Increased production of IL-1alpha and TNF-alpha in lipopolysaccharide-stimulated blood from obese patients with non-alcoholic fatty liver disease. Cytokine. 2006;33:252–257.PubMed
104.
De Groote D, Zangerle PF, Gevaert Y, et al. Direct stimulation of cytokines (IL-1 beta, TNF-alpha, IL-6, IL-2, IFN-gamma and GM-CSF) in whole blood. I. Comparison with isolated PBMC stimulation. Cytokine. 1992;4:239–248.PubMed
105.
Mayringer I, Reindl M, Berger T. A critical comparison of frequently used methods for the analysis of tumor necrosis factor-alpha expression by human immune cells. J Immunol Methods. 2000;235:33–40.PubMed
Metadata
Title
Small Intestinal Bacterial Overgrowth in Nonalcoholic Steatohepatitis: Association with Toll-Like Receptor 4 Expression and Plasma Levels of Interleukin 8
Authors
Ahmed Abu Shanab
Paul Scully
Orla Crosbie
Martin Buckley
Liam O’Mahony
Fergus Shanahan
Sanaa Gazareen
Eileen Murphy
Eamonn M. M. Quigley
Publication date
01-05-2011
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 5/2011
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-010-1447-3

Other articles of this Issue 5/2011

Digestive Diseases and Sciences 5/2011 Go to the issue

Original Article

The Neutrophil Respiratory Burst and Bacterial Digestion in Crohn’s Disease

Original Article

Role of Symptoms, Trend of Liver Tests, and Endotherapy in Management of Post-Cholecystectomy Biliary Leak

Original Article

Variable Impact of CD39 in Experimental Murine Colitis

Original Article

Musashi1 and Hairy and Enhancer of Split 1 High Expression Cells Derived from Embryonic Stem Cells Enhance the Repair of Small-Intestinal Injury in the Mouse

Original Article

Neural Autoantibody Evaluation in Functional Gastrointestinal Disorders: A Population-Based Case–Control Study

Original Article

Esophageal Motor Disorders in Adults with Eosinophilic Esophagitis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits